# Risk Assessment: LULU (Lululemon Athletica Inc.)

## Fecha: 2026-02-09

## Risk Score: HIGH

---

## QS Reassessment (Adversarial)

The QS tool scores LULU at 82/100 Tier A. The thesis accepts this uncritically. Here is what the tool misses or overstates:

### Financial Quality (Tool: 34/40 -- Adversarial: 28-30/40)

1. **ROIC spread 16.8pp is BACKWARD-LOOKING.** This is based on trailing data when US comps were positive. With Americas revenue declining 2% and comps -5%, the forward ROIC is deteriorating. If US operating margins compress by 200-300bp due to tariffs ($320M impact on ~$10.5B revenue = ~300bp), the ROIC spread shrinks materially. A more honest assessment: 12-14pp forward ROIC spread. Score should be 12-13/15, not 15/15.

2. **FCF Margin 15% is at risk.** FY2026 will see $320M in tariff-driven margin compression. On ~$10.5B revenue that is 300bp. FCF margin could drop to 12-13%. The tool uses trailing data and does not capture this. Score should be 4/5, not 5/5.

3. **FCF Consistency 4/5 is fair** but note that the FY2026 tariff hit will stress this metric going forward.

4. **Net adjustment: -4 to -6 points in Financial Quality** (28-30/40 vs 34/40)

### Growth Quality (Tool: 23/25 -- Adversarial: 18-20/25)

1. **Revenue CAGR 14% is historical.** Looking forward: Americas (70% of revenue) is declining. International grows 33% but off a smaller base. FY2025 full-year revenue guidance was CUT from $11.15-11.30B to $10.85-11.00B. The "Power of Three x2" target of $12.5B by 2026 is almost certainly going to be missed -- analysts already expect this. Forward revenue growth is more like 5-8%, not 14%. Score should be 5-6/8, not 8/8.

2. **EPS CAGR 18% is historical.** With $320M tariff headwind and US revenue declining, FY2026 EPS is expected to DECLINE mid-single-digits per Needham. Wall Street consensus is flat at best. Score should be 5-7/10, not 10/10.

3. **GM Trend "Expanding" is misleading for forward look.** GM was 58.5% in Q3 but tariffs will compress this. Management guided lower operating margins for FY2026 and won't give specific numbers until March. Score is fair at 5/5 for now but at risk.

4. **Net adjustment: -3 to -5 points in Growth Quality** (18-20/25 vs 23/25)

### Moat Evidence (Tool: 22/25 -- Adversarial: 17-19/25)

1. **GM Premium +23pp is real but under pressure.** This is the strongest moat signal. However, DTC market share dropped from 30% to 24% in just 10 months (Jan-Nov 2025). Alo Yoga went from 8% to 14% in 2 months (Sep-Nov). This pace of share loss is alarming even if GM holds today -- it signals the moat is being tested. Score should be 8/10, not 10/10.

2. **Market Position needs manual adjustment downward.** The thesis gives 5/5. But with CEO gone, product quality issues (Get Low recall, Breezethrough recall in 2024), and accelerating competitor share gains, market position is weakening. Score should be 3-4/5.

3. **ROIC Persistence is estimated, not verified.** With the structural shifts in competition and tariff environment, persistence is less certain. Score should be 5-6/7, not 7/7.

4. **Net adjustment: -3 to -5 points in Moat Evidence** (17-19/25 vs 22/25)

### Capital Allocation (Tool: 3/10 -- Adversarial: 3/10)

Fair assessment. No dividend, 4.6% insider ownership. The $1B buyback is positive but does not change the score materially.

### Adversarial QS Summary

| Category | Tool Score | Adversarial Score | Delta |
|----------|-----------|-------------------|-------|
| Financial Quality | 34/40 | 28-30/40 | -4 to -6 |
| Growth Quality | 23/25 | 18-20/25 | -3 to -5 |
| Moat Evidence | 22/25 | 17-19/25 | -3 to -5 |
| Capital Allocation | 3/10 | 3/10 | 0 |
| **TOTAL** | **82/100** | **66-72/100** | **-10 to -16** |
| **Tier** | **A** | **B (Quality Value)** | **Downgrade** |

**CRITICAL FINDING:** LULU is more likely a Tier B (66-72) than Tier A (82). The QS tool uses backward-looking data that does not capture the forward deterioration in growth, margins, and competitive position. This matters because Tier A justifies lower MoS (~15-20%) while Tier B requires ~25-30%+ MoS.

---

## Matriz de Riesgos

| # | Categoria | Riesgo | Probabilidad | Impacto | Score | Mitigante |
|---|-----------|--------|-------------|---------|-------|-----------|
| 1 | Fundamental | US business does not recover in FY2026-27 | Alta | Alto | CRITICAL | International growth partially compensates |
| 2 | Fundamental | DTC market share erosion accelerates (Alo/Vuori) | Media-Alta | Alto | HIGH | GM premium intact suggests pricing power holds for now |
| 3 | Governance | CEO vacuum + proxy fight = strategic paralysis | Alta | Alto | CRITICAL | Interim co-CEOs competent, but no permanent leader |
| 4 | Financial | Tariff impact $320M compresses margins FY2026 | Alta | Medio | HIGH | Supply chain diversification underway, selective price hikes |
| 5 | Fundamental | Serial product quality failures damage brand | Media | Alto | HIGH | Management awareness, creative team refresh |
| 6 | Governance | Chip Wilson proxy fight destabilizes board/strategy | Media | Alto | HIGH | Wilson's nominees are credible (ex-On CEO, ex-ESPN CMO) |
| 7 | Geopolitical | China growth thesis fails (geopolitical/macro) | Media | Alto | HIGH | Only ~15-20% revenue but this is THE growth engine |
| 8 | Valoracion | "Power of Three x2" miss signals broken growth model | Alta | Medio | HIGH | Market may already be pricing this in |
| 9 | Fundamental | New CEO is wrong hire (no retail experience) | Media | Alto | HIGH | Board search in progress, strong candidates |
| 10 | Legal | Securities class action + derivative lawsuits | Media | Medio | MEDIUM | Greenwashing suit dismissed; securities suit pending |
| 11 | Financial | Short interest at ~8.6% of float and rising | Baja-Media | Medio | MEDIUM | Can amplify downside on bad news |
| 12 | Valoracion | Dead money -- no catalyst for 12-18 months | Media | Medio | MEDIUM | Q4 earnings March 31 could be catalyst |
| 13 | Geopolitical | Additional tariff escalation (China 30%+, Vietnam) | Media | Medio | MEDIUM | Supply chain diversification in progress |
| 14 | ESG | Greenwashing allegations resurface | Baja | Bajo | LOW | Previous suit dismissed |

### Scoring Summary:
- **CRITICAL risks:** 2
- **HIGH risks:** 6
- **MEDIUM risks:** 4
- **LOW risks:** 2
- **Total HIGH+CRITICAL:** 8

---

## Top 3 Riesgos Criticos

### 1. CEO Vacuum + Proxy Fight = Strategic Paralysis

- **Categoria:** Governance / Fundamental
- **Descripcion:** Lululemon currently has NO permanent CEO. Calvin McDonald departed Jan 31, 2026. Two interim co-CEOs (CFO Meghan Frank + CCO Andre Maestrini) are running the company. Meanwhile, founder Chip Wilson (4.3% stake) has launched a full proxy fight nominating 3 board directors including ex-On Running co-CEO Marc Maurer. Wilson demands removal of chair David Mussafer (Advent International representative). The company's 2026 Annual Meeting will be the battleground.
- **Evidencia:**
  - CEO departure announced Dec 11, 2025
  - No permanent CEO named as of Feb 9, 2026 (40 days and counting)
  - Wilson proxy nominations filed Dec 29, 2025
  - Wilson demanded Advent board members leave (Jan 29, 2026)
  - "Get Low" leggings quality fiasco (Jan 20, 2026) happened under interim leadership
  - Bernstein downgraded citing "growing uncertainty around product revamp"
- **Probabilidad:** Alta -- this is not a risk, it is HAPPENING NOW
- **Impacto si materializa:** 20-30% additional downside. A prolonged CEO search (6+ months) combined with a divisive proxy fight could:
  - Paralyze strategic decisions (who approves the product refresh strategy?)
  - Distract management from execution during critical Spring 2026 launch
  - Create board instability if Wilson wins seats
  - Delay or derail the new CEO hire if board composition changes
- **Mitigante:** Wilson's nominees are credible operators (Maurer from On Running is relevant). If the right CEO is hired quickly, this resolves. Interim co-CEOs know the business well.
- **Kill condition?:** YES -- if CEO search extends past June 2026 (6+ months), or if proxy fight results in fragmented board with no clear strategic direction, this becomes a structural governance problem.

### 2. US Business Structural Decline Masked as Cyclical

- **Categoria:** Fundamental
- **Descripcion:** The thesis asserts US weakness is CYCLICAL (product staleness) not STRUCTURAL (moat erosion). I challenge this assessment. The evidence is more ambiguous than the thesis admits:
  - Americas comps: -5% in Q3 2025 (accelerating decline from -2% in prior quarters)
  - DTC market share: dropped from 30% to 24% in 10 months (Jan-Nov 2025)
  - Alo Yoga: grew from 8% to 14% DTC share in just 2 months
  - Two consecutive product recalls (Breezethrough 2024, Get Low 2026)
  - UBS warns US sales "may not turn sustainably positive in 2026"
  - 23 analysts consensus: HOLD (not Buy). 78% say Hold.
- **Evidencia:**
  - The thesis claims GM 58.5% = moat intact. But GM can lag market share loss by 2-3 years. Nike maintained GM even as it lost share before the GM eventually compressed. This is a classic "lagging indicator" trap.
  - Alo Yoga's 88% YoY growth during peak periods and Vuori's 33% YoY growth show competitor momentum is real, not noise.
  - The product quality failures (Get Low and Breezethrough) suggest innovation execution problems, not just "product staleness" that management can easily fix.
  - Among high-income consumers ($200k+), Vuori's share rose from 11.87% to 15.31% (2023-2025). This is Lululemon's CORE demographic being poached.
- **Probabilidad:** Media-Alta (40-50%)
- **Impacto si materializa:** If this is structural, the Bear Case FV of $190 is too optimistic. A structural decline scenario looks like:
  - Americas revenue declines 3-5% annually for 3+ years
  - GM compresses 200-400bp as pricing power erodes
  - P/E re-rates to 8-10x (closer to Under Armour levels)
  - Fair value: $120-140 (30-40% below current price)
- **Mitigante:** Spring 2026 product refresh (35% newness) is a real test. If Spring launch succeeds and Q1 FY2026 shows Americas comp improvement, this risk diminishes. But this is a HOPE, not evidence.
- **Kill condition?:** Already in thesis (3 quarters negative global comps). Should ADD: "DTC market share falls below 20%" as kill condition, since share erosion is the leading indicator of moat decay.

### 3. Tariff-Driven Margin Destruction + Tariff Escalation Risk

- **Categoria:** Financial / Geopolitical
- **Descripcion:** The thesis calls tariff impact "marginal (~100bp GM)" and "Low" impact. This is SEVERELY understated. The actual numbers:
  - FY2025 tariff impact: $240 million gross profit reduction
  - FY2026 tariff impact: $320 million operating margin reduction
  - On ~$10.5B revenue, $320M = ~300bp margin compression
  - Current tariff assumptions: 30% on China, 10% on other countries
  - 40% of products made in Vietnam, 30% of fabrics from China
  - De minimis exemption removal adds additional cost
  - Trump has already escalated tariffs further on South Korea (where some suppliers are)
- **Evidencia:**
  - Management refused to give FY2026 operating margin guidance, only saying they'll update in March
  - Selective price increases risk losing customers "during an already fragile spending environment"
  - Supply chain diversification to Cambodia/Sri Lanka takes 12-24 months to execute
  - Further tariff escalation is a LIVE risk (current world view: "Incertidumbre comercial global ALTA y subiendo, probabilidad 60-70%")
  - If tariffs on Vietnam increase from 10% to 25% (plausible), the impact roughly doubles
- **Probabilidad:** Alta (tariffs already in place) + Media for escalation
- **Impacto si materializa:**
  - Base tariff impact: 300bp margin compression already baked in ($320M)
  - Escalation scenario (Vietnam to 25%): additional 150-200bp (another $150-200M)
  - Total impact: 450-500bp margin compression
  - Operating margin could fall from ~22% to 17-18% (vs thesis assumption of 24-25% normalized)
  - FCF margin drops to 10-11% from 15%
  - This alone would reduce DCF fair value by 20-25%
- **Mitigante:** Pricing power (GM 58.5% suggests room to absorb), supply chain diversification, vendor negotiations. But management themselves said they cannot raise prices aggressively "during a fragile spending environment."
- **Kill condition?:** Should ADD: "Operating margin falls below 18% for 2 consecutive quarters" as kill condition.

---

## Risks NOT Mentioned in Thesis

| Riesgo | Severidad | Mencionado en thesis? | Comentario |
|--------|-----------|----------------------|------------|
| **Chip Wilson proxy fight for board control** | HIGH | Minimizado -- thesis says "Chip Wilson gains board control" as kill condition but does not discuss the ACTIVE proxy fight happening NOW | This is not a hypothetical. Wilson has filed nominations. Annual meeting is upcoming. Board instability is a current reality, not a future risk. |
| **Serial product quality failures (Breezethrough + Get Low)** | HIGH | NO | Two product recalls in 12 months. The thesis mentions "product refresh" as catalyst but ignores that the last two major product launches FAILED. This pattern suggests innovation execution problems, not just "staleness." |
| **"Power of Three x2" revenue target will be missed** | HIGH | NO | $12.5B by 2026 was the target. FY2025 revenue guidance is $10.85-11.0B. Even with 10% growth, FY2026 would be ~$12B. Missing a flagship strategic target undermines management credibility. |
| **Securities class action lawsuit (Patel v. LULU)** | MEDIUM | NO | Active securities fraud class action in SDNY alleging false statements about inventory, Breezethrough launch, and Americas stagnation. Amended complaint filed March 2025. If this survives motion to dismiss, settlement could be $50-200M. |
| **Tariff impact understated by 3x** | HIGH | Minimizado -- thesis says "~100bp GM" and "Low impact" | Actual impact is $320M or ~300bp. Thesis understates the magnitude by roughly 3x. Management itself refused to give FY2026 margin guidance. |
| **Short interest rising (8.6% of float)** | MEDIUM | NO | 7.58M shares short, up from 6.95M in prior period. Rising short interest can amplify selling pressure on negative catalysts. |
| **Analyst consensus is HOLD, not Buy** | MEDIUM | NO | 23 analysts: 78% Hold, only 22% Buy/Strong Buy. Consensus price target ~$212 implies only 23% upside from $173 -- much less than thesis's 52%. |
| **Insider net selling** | MEDIUM | NO | $3.3M in net insider selling over 90 days. Calvin McDonald and others selling on exit. Not massive but directionally negative. |
| **De minimis exemption removal** | MEDIUM | NO | Beyond tariffs, the removal of de minimis exemption adds another layer of cost for international fulfillment. Supply Chain Dive reports this specifically strains LULU's fulfillment model. |
| **Co-CEO structure is inherently unstable** | MEDIUM | Minimizado | Thesis says "Co-CEOs interim experimentados." History shows co-CEO structures rarely work long-term (see Deutsche Bank, SAP). Decision-making slows, accountability diffuses. |

---

## DCF Tool Analysis

### Tool Output (Baseline)

```
BEAR: $190.56 (+10.2% MoS)
BASE: $241.31 (+39.6% MoS)
BULL: $313.24 (+81.2% MoS)
```

### Problems with Tool Output

1. **Net Debt: $0.73B.** The tool correctly subtracts net debt. However, LULU has operating lease obligations that are NOT captured. As a retailer with 700+ stores, operating lease liabilities are material (likely $2-3B based on industry norms). This is off-balance-sheet risk the tool ignores.

2. **Growth assumptions likely use historical 14% CAGR.** Forward growth should be 5-8% given Americas weakness and tariff headwinds. If the tool uses 5% base growth (default), this is actually more conservative than the thesis's 10-12%. But if it uses historical CAGR, the output is too high.

3. **Terminal value sensitivity.** At 3% terminal growth (thesis assumption), the terminal value dominates. For a company with an uncertain competitive position and an industry growing at 7.2%, 3% terminal growth is reasonable but relies on LULU maintaining relevance for decades.

4. **Tariff impact not captured.** The DCF tool does not adjust for the $320M operating margin hit. If we reduce FCF by $250M (post-tax tariff impact), the fair value drops by ~$20-25 per share.

### Adversarial DCF Adjustment

Starting from tool Base Case of $241:
- Tariff impact adjustment: -$20 to -25
- Lower growth rate correction: -$15 to -20 (if tool used historical growth)
- Lease obligation adjustment: -$10 to -15
- Competition risk haircut (5%): -$10

**Adversarial Base Case DCF: $170-190** (vs thesis $241)

---

## Fair Value Challenge

### Thesis FV: $261 Weighted

| Method | Thesis FV | Adversarial FV | Delta |
|--------|----------|----------------|-------|
| DCF Base (60%) | $241 | $175-190 | -21% to -27% |
| P/E 20x (40%) | $290 | $200-220 | -24% to -31% |
| **Weighted** | **$261** | **$185-203** | **-22% to -29%** |

### Why Thesis FV is Inflated

1. **P/E 20x is too generous.** The thesis applies a 50% haircut to the 5-year average P/E of 40x. But the 5-year average includes the hypergrowth period when LULU was growing revenue 25%+ and had no competition. With forward growth of 5-8%, negative US comps, and tariff headwinds, a P/E of 15-17x is more appropriate. This is supported by the analyst consensus target of ~$212 which implies ~15x forward P/E.

2. **DCF uses backward-looking financials.** As discussed above, forward FCF is lower due to tariffs, slower growth, and potential competitive margin pressure.

3. **EPS estimate may be too high.** Thesis uses ~$14.50 EPS for P/E method. With $320M tariff impact, FY2026 EPS could be $12-13 (Needham expects mid-single-digit EPS decline). At 15x P/E on $12.50 EPS = $187.

4. **No governance/execution discount.** The thesis applies zero discount for: (a) no permanent CEO, (b) active proxy fight, (c) two product recalls in 12 months. A 5-10% governance discount is warranted.

### Adversarial Fair Value

| Scenario | Adversarial FV | Probability |
|----------|---------------|-------------|
| Bear (structural US decline + tariff escalation) | $120-140 | 25% |
| Base (cyclical recovery delayed, tariffs bite) | $175-195 | 50% |
| Bull (quick CEO hire, product refresh works, tariff mitigation) | $250-280 | 25% |

**Expected Value: 0.25 * $130 + 0.50 * $185 + 0.25 * $265 = $191**

**Adversarial MoS vs current price $173: +10.7%**

This is a THIN margin of safety for a company with 8 HIGH/CRITICAL risks, no permanent CEO, an active proxy fight, and $320M in tariff headwinds.

---

## Kill Conditions Assessment

### Thesis Kill Conditions (5)

| # | Kill Condition | Assessment |
|---|---------------|------------|
| 1 | GM < 50% | Reasonable but too generous. By the time GM hits 50% from 58.5%, massive value destruction has occurred. Should be tighter: GM < 55% as warning, < 52% as kill. |
| 2 | 3 quarters negative global comps | Good but US is already 2+ quarters negative. "Global" masks the problem since International growth offsets. Should separate: US comps negative 4+ quarters as kill. |
| 3 | FCF negative 2+ quarters | Reasonable. |
| 4 | Bad CEO hire | Vague. How do you define "bad"? Need specifics: no retail experience, no DTC experience, or insider with no brand-building track record. |
| 5 | Chip Wilson disruptive board control | Already partially happening. Wilson has filed proxy nominations. Needs to be more specific about trigger. |

### Missing Kill Conditions (Should Add)

1. **DTC market share falls below 20%** (currently 24%, down from 30%). This is the canary in the coal mine for moat erosion.
2. **No permanent CEO within 6 months of McDonald departure** (i.e., by July 2026). Extended leadership vacuum is governance failure.
3. **Operating margin falls below 18% for 2 consecutive quarters.** This would indicate tariff impact is not being mitigated and pricing power is insufficient.
4. **China revenue growth decelerates below 10%.** China is the thesis's growth engine. If it stalls, the entire "International compensates" narrative collapses.
5. **Analyst consensus target falls below $175** (below current price). If the professional community gives up on recovery, the stock becomes a "falling knife."

---

## Riesgo Agregado

- Numero de riesgos HIGH+CRITICAL: **8**
- Riesgos correlacionados: **YES**
  - CEO vacuum + Proxy fight + Product failures are CORRELATED (all governance/execution chain)
  - Tariff impact + US decline + Margin compression are CORRELATED (all squeeze profitability simultaneously)
  - China growth dependency + Geopolitical risk are CORRELATED
- **The correlation matters because:** If governance fails AND tariffs escalate AND US stays weak, these risks compound rather than offset. In a "bad scenario," you get ALL of them at once.

### Risk Score Final: **HIGH**

Justification: 8 HIGH/CRITICAL risks with significant correlation. The thesis's characterization of LULU as a "fallen angel" with "cyclical, not structural" problems is at best premature and at worst wrong. The evidence for structural moat erosion (DTC share loss 30% to 24%, accelerating competitor gains, serial product failures) is stronger than the thesis admits. The governance situation (no CEO, proxy fight) is a current reality, not a future risk. And the tariff impact ($320M) is 3x what the thesis claims.

---

## Comparison with Prior Adversarial Reviews

| Metric | Pattern (12/13 prior) | LULU |
|--------|----------------------|------|
| Thesis FV inflated? | Yes, avg -15% | Yes, -22% to -29% |
| QS overstated? | Yes, all 12/13 | Yes, 82 -> 66-72 (Tier A -> Tier B) |
| Risks omitted? | Yes, avg 5+ | Yes, 10 material risks not in thesis |
| Bear case too optimistic? | Yes, pattern | Yes, thesis bear $190 vs adversarial bear $130 |

The pattern holds. This thesis follows the same overoptimism pattern as every other thesis we have reviewed adversarially.

---

## ðŸ”„ META-REFLECTION

### Dudas/Incertidumbres
- **The cyclical vs structural debate is genuinely uncertain.** I lean toward "more structural than thesis admits" but the Spring 2026 product refresh is a real test. If 35% newness drives positive US comps in Q1 FY2026 (results in June), the structural thesis weakens.
- **Chip Wilson's nominees might actually be good for the company.** Marc Maurer (ex-On Running co-CEO) built a premium athletic brand from scratch. If he becomes CEO or influences strategy, it could be a positive catalyst. But proxy fights are messy regardless of nominee quality.
- **I could not verify the exact FY2025 Q4 earnings results.** Q4 fiscal year 2025 earnings will be reported March 31, 2026. The pre-announcement on Jan 12 said "high end of guidance" ($3.5-3.585B revenue, $4.66-4.76 EPS). So Q4 may be decent -- but this is backward-looking.

### Riesgos que Podrian Estar Subestimados
- **DTC market share erosion could accelerate further.** The pace of Alo Yoga's gain (8% to 14% in 2 months) is extraordinary. If this continues through Spring 2026, the moat narrative shatters.
- **China geopolitical risk.** The thesis assumes China is a growth engine. But world/current_view.md says "Evitar China. Riesgo politico alto." If there is a US-China trade escalation or consumer boycott of Western brands in China (has happened before), LULU loses its growth engine overnight.
- **Serial product failures may indicate deeper organizational problems.** Breezethrough (2024) and Get Low (2026) -- both premium launches that failed on basic quality. This suggests a systemic quality control issue, not random bad luck. The thesis's product refresh catalyst depends on execution that has FAILED twice recently.

### Discrepancias con Thesis
1. **QS overstated by 10-16 points (Tier A vs Tier B).** This is the most consequential discrepancy because it changes the required MoS.
2. **Tariff impact understated by 3x.** Thesis says ~100bp, actual is ~300bp ($320M).
3. **Fair value inflated by 22-29%.** Thesis $261 vs adversarial $185-203.
4. **Thesis calls CEO departure "manageable."** A 40-day CEO vacuum with an active proxy fight is NOT manageable. It is a governance crisis.
5. **Thesis says "1/10 value trap factors."** I count 3-4 of 10 when properly assessed:
   - Loss of market share >2pp 3yr: YES (DTC 30% to 24% in 10 months alone)
   - Product failures: YES (2 recalls in 12 months = execution problems)
   - CEO departure: YES (leadership instability)
6. **Bear case too optimistic.** Thesis bear $190, adversarial bear $120-140. The thesis bear assumes US "flat/negative 2 years" but does not model a true structural decline scenario where Alo/Vuori take another 5-10pp of share.
7. **The thesis draws a parallel with NVO.** But NVO has a pharmaceutical moat (patents, FDA approvals, manufacturing complexity) that is structurally harder to erode than a fashion brand. Lululemon's moat is brand + community -- both of which CAN be eroded by competitors, as Alo Yoga is demonstrating.

### Sugerencias para el Sistema
1. **Create a "governance risk score" component.** QS does not capture CEO vacuums, proxy fights, or board instability. For LULU, this is the #1 risk and it gets zero weight in QS.
2. **DCF tool should accept manual FCF overrides.** For companies with known one-time or structural cost increases (tariffs), the tool should allow inputting adjusted FCF rather than only using historical.
3. **The "cyclical vs structural" determination needs a more rigorous framework.** The thesis calls it cyclical based on GM being intact, but DTC market share loss is a LEADING indicator of moat erosion that should weigh more heavily.

### Preguntas para Orchestrator
1. **Given adversarial FV of $185-203 and current price $173, the MoS is only 7-17%.** For a Tier B company (adversarial QS 66-72) with 8 HIGH/CRITICAL risks, is this sufficient? Precedents suggest Tier B needs 25-30%+ MoS. This implies current price is near fair value or slightly above on a risk-adjusted basis.
2. **Should the position be downgraded to PROBATION?** The adversarial review found materially more risk than the thesis acknowledged. Given our pattern of finding 15% average FV inflation in prior reviews, the original purchase at $171.62 may have been premature.
3. **Q4 earnings March 31 is the next data point.** Should we set a stop-loss or reduce position before earnings given the governance risks and tariff guidance uncertainty?
4. **How do we weight the Chip Wilson proxy fight?** His nominees are arguably BETTER than current board for a retail turnaround. But the process itself is destabilizing.

---

## Sources

### Earnings and Financial Data
- [Lululemon Q4 FY2025 Pre-announcement (Jan 12, 2026)](https://corporate.lululemon.com/media/press-releases/2026/01-12-2026-113012292)
- [Lululemon Q3 FY2025 Earnings Call Transcript](https://www.fool.com/earnings/call-transcripts/2025/12/12/lululemon-lulu-q3-2025-earnings-call-transcript/)
- [Lululemon Results Center](https://corporate.lululemon.com/investors/financial-information/results-center)
- [MarketBeat: LULU Earnings](https://www.marketbeat.com/stocks/NASDAQ/LULU/earnings/)

### CEO Transition and Proxy Fight
- [Lululemon CEO Succession Plan (Dec 11, 2025)](https://corporate.lululemon.com/media/press-releases/2025/12-11-2025-210527531)
- [Retail Dive: Chip Wilson proxy fight](https://www.retaildive.com/news/chip-wilson-lululemon-board-proxy-fight/808727/)
- [SGB Online: Lululemon responds to founder's proxy battle](https://sgbonline.com/lululemon-responds-to-founders-proxy-battle/)
- [Yahoo Finance: Wilson seeks Advent removal](https://finance.yahoo.com/news/lululemon-founder-chip-wilson-seeks-114118285.html)
- [Bloomberg: Wilson nominates three board candidates](https://www.bloomberg.com/news/articles/2025-12-29/lululemon-founder-nominates-three-new-board-candidates)
- [Sahm Capital: Wilson activist campaign](https://www.sahmcapital.com/news/content/chip-wilsons-activist-campaign-puts-lululemon-governance-and-quality-under-scrutiny-2026-01-29)

### Competition and Market Share
- [Retail Dive: Alo Yoga, Vuori gaining share](https://www.retaildive.com/news/alo-yoga-vuori-gaining-activewear-market-share/714384/)
- [CNBC: Vuori $5.5B valuation taking share from Lululemon](https://www.cnbc.com/2024/12/19/how-vuori-is-taking-on-lululemon.html)
- [StockTwits: Lululemon market share losses](https://stocktwits.com/news-articles/markets/equity/lululemons-stretch-is-snapping-market-share-losses-executive-turmoil-testing-investors-patience/cLIxeFVREnT)

### Product Quality Issues
- [Bloomberg: Get Low leggings pulled (Jan 20, 2026)](https://www.bloomberg.com/news/articles/2026-01-20/lululemon-pulls-new-get-low-collection-days-after-debut-amid-complaints)
- [Business of Fashion: Lululemon blames customers after see-through tights](https://www.businessoffashion.com/articles/sports/lululemon-blames-customers-again-after-see-through-tights-fiasco/)
- [Yahoo Finance: Wilson outraged over see-through leggings](https://finance.yahoo.com/news/lululemon-founder-outraged-over-see-163133398.html)

### Tariff Impact
- [Supply Chain Dive: De minimis elimination strains LULU](https://www.supplychaindive.com/news/lululemon-de-minimis-elimination-impact-2025/760670/)
- [Nasdaq: Global trade policy risks and LULU supply chain](https://www.nasdaq.com/articles/can-global-trade-policy-risks-reshape-lululemons-supply-chain)
- [Yahoo Finance: Margin squeezes as tariffs and markdowns bite](https://finance.yahoo.com/news/lululemon-q2-metrics-margin-squeezes-141900167.html)

### Analyst Ratings
- [MarketBeat: LULU Forecast and Price Target](https://www.marketbeat.com/stocks/NASDAQ/LULU/forecast/)
- [Barchart: Hard to have conviction in LULU](https://www.barchart.com/story/news/35613695/its-hard-to-have-conviction-in-lululemon-stock-right-now-according-to-analysts-should-you-sell-lulu-here)
- [SGB Online: More stock downgrades on doubts for US recovery](https://sgbonline.com/exec-lululemon-faces-stock-downgrades-on-growing-doubts-on-quick-u-s-recovery/)

### Litigation
- [SEC Filing: LULU 10-Q (Nov 2, 2025)](https://www.sec.gov/Archives/edgar/data/1397187/000139718725000055/lulu-20251102.htm)
- [ClassAction.org: Gyani v. Lululemon](https://www.classaction.org/media/gyani-v-lululemon-athletica-inc-et-al.pdf)

### Insider Activity and Short Interest
- [MarketBeat: LULU Insider Trades](https://www.marketbeat.com/stocks/NASDAQ/LULU/insider-trades/)
- [MarketBeat: LULU Short Interest](https://www.marketbeat.com/stocks/NASDAQ/LULU/short-interest/)

### Strategic Analysis
- [Seeking Alpha: LULU discounting 2026 recovery too early](https://seekingalpha.com/article/4861167-lululemon-the-market-is-discounting-a-2026-recovery-too-early)
- [Motley Fool: Down 10% in 2026, is LULU a buy?](https://www.fool.com/investing/2026/01/27/down-10-already-in-2026-is-lululemon-stock-a-buy/)
- [Retail Dive: Lululemon's downward spiral](https://www.retaildive.com/news/lululemon-athleisure-downward-spiral-innovation-turnaround/760318/)
